Investor Presentaiton

Atos Medical financial assumptions 57 Organic growth and Organic growth 8-10% EBITDA margin . EBITDA margin in the mid-30s level EPS impact • Increasingly EPS accretive from FY 2022/23 Synergies Financing Integration, transaction and financing costs Impact on balance sheet and capital allocation policy Purchase Price Allocation • • . • • Estimated run-rate operational synergies of up to DKK 100m from utilising Coloplast infrastructure with full impact estimated from FY 2023/24 Structured as a 100% cash payment financed through debt financing The blended interest rate for the debt financing package is expected around 3.2% in FY 2022/23, achieved through the bond issuance, hedges on the 8-year tranche and the 5-year tranche, as well as the secured interest rate on the credit facility One-off transaction and integration costs including legal fees, advisory fees and insurance costs etc., and P&L integration costs of around DKK 171m in FY 2021/22, treated as special items. An additional DKK ~50 million in special items expected in 2022/23. Capex integration costs of up to DKK 150m split over 21/22-23/24, of which the vast majority IT capex. By the end of Strive25, leverage is expected to be within the target range of 1-2x NIBD/EBITDA No changes to Coloplast's capital allocation policy to return excess liquidity through dividends and share buy-back. Updated target payout ratio of 60-80% of net profit Around 75% of the purchase value will be treated as goodwill. The remaining 25% will be treated as intangibles, to be amortised over approximately 15 years Deal timing • Closed on 31 January, 2022 Page 57 Coloplast

View entire presentation